Funding shortfall
The company depends on external capital to fund operations and development.
- Scope
- R&D, production scale-up, and basic operating expenses
- Materiality
- high
Zivo Bioscience, Inc.
Zivo Bioscience, Inc. is a U.S.-based research and development company focused on proprietary algal and bacterial strains for applications in human health, animal health, and agtech. Its business centers on developing bioactive compounds, algal biomass, and related intellectual property for therapeutic, nutritional, and functional ingredient uses.
31,1 %
−8 513,4 %
+468,6 %
0.80
0.80
| % | |
|---|---|
| Biotech product candidates | 20% Bioactive materials and product candidates derived from proprietary algae for human and animal health applications. |
| Agtech algal biomass | 60% Cultivated algal biomass sold or developed for food, nutritional, and functional ingredient uses. |
| Licensing and commercialization rights | 20% License-related economics and participation arrangements tied to ZIVO-derived bioactive ingredients. |
Zivo sells into two broad end markets: animal health and agtech/nutrition. On the biotech side, the company targets...
- Animal health companies and producersprimary
Buy or license ZIVO-derived solutions for poultry coccidiosis, bovine mastitis, avian influenza, and companion animal health.
- Food and nutrition ingredient buyersprimary
Purchase algal biomass for use in green powders, supplements, and fortified food applications.
- Commercialization and licensing partnerssecondary
Partner on late-stage development, regulatory work, and commercialization of bioactive compounds.
- Skin care and personal care formulatorsemerging
Evaluate algal biomass as a functional ingredient for topical and ingestible skin health products.
Zivo is headquartered in the United States, while its algal biomass production is currently located in Peru...
- •United States is the corporate and development base
- •Peru is the production site for proprietary algal biomass
- •North America is an initial commercial focus for Zivolife
- •Global animal health markets are a target for product candidates
- •International partners matter for regulatory and commercialization reach
Zivo’s strategy is to advance proprietary algae-derived compounds through regulatory, clinical, and commercial...
01
Commercialize algal biomass ingredientsshort-term
Ingredient sales can generate nearer-term revenue while the biotech pipeline matures.
02
Advance animal health product candidatesmedium-term
Animal health indications offer a clearer path to value creation and partnering.
03
Build regulatory readinessmedium-term
GRAS, NDI, and related approvals support broader ingredient and product commercialization.
04
Secure strategic funding and partnershipsshort-term
Development and scale-up require external capital and commercialization partners.
Zivo is exposed to development-stage biotech risk, including uncertain clinical, regulatory, and commercialization...
Regulatory and clinical failure
Product candidates require successful studies and approvals before commercialization.
- Scope
- Coccidiosis, mastitis, avian influenza, human immune modulation
- Materiality
- high
Commercialization and partner execution
The company relies on strategic partners for late-stage development and market access.
- Scope
- Licensing, distribution, and commercialization timelines
- Materiality
- medium
Production scale-up risk
Commercial algae cultivation must be scaled reliably from pilot to full production.
- Scope
- Peru-based ponds, processing equipment, biomass output
- Materiality
- medium
Market adoption risk
Ingredient and animal health buyers may prefer established alternatives.
- Scope
- Green powders, supplements, skin care, poultry health
- Materiality
- medium
Revenue recognition for product sales and contracts
Affects quarterly revenue timing and comparability
License fee revenue share arrangements
Affects revenue presentation and obligations
Stock-based compensation
Affects operating expense and loss measures
Going-concern and liquidity assumptions
Affects risk disclosures and valuation judgments
: 29.4.2026